New York – United States
Dyspepsia Drug Market is expected to grow in the forecast period due to the increasing prevalence of dyspepsia and the rising adoption of unhealthy lifestyles. The market is also influenced by the increase in the prevalence of metabolic disorders. However, the global dyspepsia drug market is expected to be hampered by the possible side effects of the drugs used for dyspepsia and the increasing preference for natural and herbal remedies. The growing aging population and rise in drug approval are expected to act as opportunities for market growth. However, stringent regulations and a lack of awareness about dyspepsia among the population is expected to challenge the market growth.
Data Bridge Market Research analyzes that the global dyspepsia drug market is expected to grow at a CAGR of 5.2% during the forecast period of 2023 to 2030.
Download the PDF Sample Report (Including FULL TOC, Graphs, and Tables) of Dyspepsia Drug Market report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dyspepsia-drug-market&Shri
Dyspepsia, commonly known as indigestion, is the pain and discomfort experienced in the abdomen after eating. It is usually a sign of an underlying condition like GERD (gastroesophageal reflux disease), gallbladder, and ulcer disease. Treatment for dyspepsia depends on the cause and severity. Treating an underlying condition or changing a person’s medication will reduce dyspepsia. Dyspepsia is divided into 2 main categories: “organic” and “functional dyspepsia” (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Functional dyspepsia (dis-PEP-see-uh) is a term for recurring symptoms of an upset stomach that have no obvious cause. Functional dyspepsia is also called non ulcer dyspepsia.
DRIVERS
- Increasing prevalence of dyspepsia
- Rise in the adoption of unhealthy lifestyle
OPPORTUNITY
- Growing aging population
Recent Developments
- In April 2023, Sanofi announced that it had completed the acquisition of Provention Bio, Inc. This acquisition has helped the company in the expansion of its business in general medicine.
- In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.
Major Players
Data Bridge Market Research recognizes the following companies as the major dyspepsia drug market players in dyspepsia drug market are Bayer AG (Germany), Mankind Pharma (India), Cadila Pharmaceuticals. (India), Salix Pharmaceuticals, and its affiliates (U.S.), Sanofi (France), Aosaikand Pharmaceutical Co., Ltd. (China), Hanmi Pharm. Co., Ltd. (Korea), ANI Pharmaceuticals, Inc (U.S.), Asterisk Laboratories (I) Pvt. Ltd (India), Lupin (India), AstraZeneca (U.K.), RedHill Biopharma Ltd. (Israel), Abbott (U.S.), McNeil Consumer Pharmaceuticals Co. (U.S.), Otsuka Pharmaceutical Co., Ltd.(Japan), Takeda Pharmaceutical Company Limited. (Japan), ZERIA Pharmaceutical Co., Ltd (Japan), Procter & Gamble (U.S.), Perrigo Company plc (Ireland), Reckitt Benckiser (England), WOODWARD PHARMA (U.S.) and Prestige Consumer Healthcare Inc. (U.S.), among others.
Market Developments:
- In April 2023, Lupin announced that it had launched a regional reference laboratory in Bengaluru. Thus, strengthening its presence in South India.
- In November 2022, Abbott announced that it had been awarded by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
- In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, and a privately owned biopharmaceutical company. This helps the organization in developing more revenue.
- In March 2022, AstraZeneca partnered with The National Fish and Wildlife Foundation (NFWF) to plant and sustain one million trees in the United States by the end of 2025. This initiative is part of the Company’s flagship Ambition Zero Carbon program to decarbonize its global operations by eliminating, reducing, and substituting for our greenhouse gas emissions and becoming carbon negative across our value chain by 2030, in line with science-based targets. This helps the organization in developing its image in terms of the green world.
- In September 2020, Cadila Pharmaceuticals announced the launch of Obetocad in India, a generic version of Ocaliva (Obeticholic Acid) primarily used for the treatment of Primary Biliary Cholangitis. This product launch has helped the company in product portfolio expansion.
Browse a Detailed Summary of Dyspepsia Drug Market Research Report @ https://www.databridgemarketresearch.com/reports/global-dyspepsia-drug-market?Shri
Dyspepsia Drug Market Segmentation
Type
- Non-Ulcer Dyspepsia
- Organic Dyspepsia
- Drug Induced Dyspepsia
- Others
Treatment Type
- Medication
- Surgery
- Based on treatment type, global dyspepsia drug market is segmented into medication and surgery.
Drug Type
- Branded
- Generic
- Based on drug type global dyspepsia drug market is segmented into generic, and branded.
Prescription
- Without Prescription Drugs
- Prescription Drugs
Route of Administration
- Oral
- Injectable
Gender
- Male
- Female
End User
- Hospitals
- Clinics
- Homecare Settings
- Specialty Clinics
- Ambulatory Centers
- Academic and Government Research Institutes
- Others
Distribution Channel
- Direct Tender
- Retail Sales
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Media Contact
Sopan Gedam
Organization: Data Bridge Market Research
Phone: +1-888-387-2818
Email: sales@databridgemarketresearch.com
Web: www.databridgemarketresearch.com